Kazia Therapeutics Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
6
- Stock Symbol
-
NV9
- Investments
-
4
Kazia Therapeutics General Information
Description
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Contact Information
Website
www.kaziatx.comCorporate Office
- Three International Towers
- Level 24, 300 Barangaroo Avenue
- Sydney, New South Wales 2000
- Australia
Corporate Office
- Three International Towers
- Level 24, 300 Barangaroo Avenue
- Sydney, New South Wales 2000
- Australia
Kazia Therapeutics Timeline
Kazia Therapeutics Financials Summary
As of 31-Dec-2025, Kazia Therapeutics has a trailing 12-month revenue of $27.1K.
|
In Thousands, USD |
TTM 31-Dec-2025 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 | FY 2023 30-Jun-2023 |
|---|---|---|---|---|
| Revenue | 27 | 27 | 1,513 | 0 |
| EBITDA | (15,861) | (13,967) | (16,509) | (12,699) |
| Net Income | (14,692) | (13,395) | (17,549) | (13,758) |
| Total Assets | 47,603 | 3,959 | 14,427 | 18,590 |
| Total Debt | 66 | 259 | 424 | 1,189 |
Kazia Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kazia Therapeutics Comparisons
Industry
Financing
Details
Kazia Therapeutics Competitors (2)
One of Kazia Therapeutics’s 2 competitors is Blueprint Medicines, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Blueprint Medicines | Formerly VC-backed | Cambridge, MA | ||||
| Nimbus Therapeutics | Venture Capital-Backed | Boston, MA |
Kazia Therapeutics Patents
Kazia Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2016901074-A0 | Pharmaceutical compositions | Inactive | 22-Mar-2016 | ||
| AU-2017201817-A1 | Pharmaceutical compositions | Inactive | 22-Mar-2016 | ||
| WO-2016187667-A1 | Functionalised and substituted indoles as anti-cancer agents | Inactive | 27-May-2015 | ||
| AU-2015291788-A1 | Functionalised and substituted carbazoles as anti-cancer agents | Inactive | 16-Jul-2014 | ||
| US-20170158636-A1 | Functionalised and substituted carbazoles as anti-cancer agents | Inactive | 16-Jul-2014 | C07D209/88 |
Kazia Therapeutics Signals
Kazia Therapeutics Investments & Acquisitions (4)
Kazia Therapeutics’s most recent deal was a Corporate Asset Purchase with QIMR Berghofer Medical Research Institute (Global Rights to the SETDB1 Platform) for . The deal was made on 13-Apr-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| QIMR Berghofer Medical Research Institute (Global Rights to the SETDB1 Platform) | 13-Apr-2026 | Corporate Asset Purchase | Buildings and Property | ||
| Glioblast | 31-Oct-2016 | Merger/Acquisition | Biotechnology | ||
| CanTx | 06-Nov-2013 | Joint Venture | Drug Discovery | ||
| Triaxial Pharmaceuticals | 05-Dec-2012 | Merger/Acquisition | Biotechnology |
Kazia Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Kazia Therapeutics Exits (1)
Kazia Therapeutics’s most recent exit was on 05-Dec-2012 from Triaxial Pharmaceuticals. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Triaxial Pharmaceuticals | 05-Dec-2012 | Completed |
|
Kazia Therapeutics FAQs
-
When was Kazia Therapeutics founded?
Kazia Therapeutics was founded in 1994.
-
Where is Kazia Therapeutics headquartered?
Kazia Therapeutics is headquartered in Sydney, Australia.
-
What is the size of Kazia Therapeutics?
Kazia Therapeutics has 6 total employees.
-
What industry is Kazia Therapeutics in?
Kazia Therapeutics’s primary industry is Biotechnology.
-
Is Kazia Therapeutics a private or public company?
Kazia Therapeutics is a Public company.
-
What is Kazia Therapeutics’s stock symbol?
The ticker symbol for Kazia Therapeutics is NV9.
-
What is Kazia Therapeutics’s current revenue?
The trailing twelve month revenue for Kazia Therapeutics is $27.1K.
-
Who are Kazia Therapeutics’s competitors?
Blueprint Medicines and Nimbus Therapeutics are competitors of Kazia Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process